Recommended 5-FU Dosing for Concurrent Chemoradiotherapy in Rectal Cancer
For concurrent chemoradiotherapy with radiation in locally advanced rectal cancer, use 5-FU as a continuous infusion at 225 mg/m²/day throughout radiotherapy, 5 days per week 1.
Primary Dosing Regimen
The most current guideline-based recommendation is:
- 5-FU continuous infusion: 225 mg/m²/day, administered continuously during radiotherapy, 5 days per week 1
- This is delivered concurrently with pelvic radiation (45.0-50.4 Gy over 25-28 fractions)
Alternative Acceptable Regimens
If continuous infusion is not feasible, alternative fluoropyrimidine-based options include:
Capecitabine (Preferred Alternative)
- 825 mg/m² twice daily, 5 days per week during all days of radiotherapy 1
- This oral alternative has demonstrated equivalence to infusional 5-FU in multiple trials 2
Bolus 5-FU (Less Preferred)
Historical regimens used bolus dosing, though continuous infusion is superior 3:
- 1000 mg/m² on days 1-4 and 29-32 of radiotherapy 4
- Alternative: 500 mg/m² days 1-5, then 600 mg/m² with leucovorin on days 16,23,30, and 37 5
Bolus 5-FU should only be considered for patients unable to tolerate capecitabine or continuous infusion 2, as continuous infusion demonstrates better outcomes with less hematologic toxicity 6, 3.
Radiation Dosing Context
The chemotherapy is delivered with:
- Standard pelvic dose: 45.0-50.4 Gy over 25-28 fractions (1.8-2.0 Gy per fraction) 1
- Additional boost: 5.4 Gy/3 fractions for preoperative cases 1
- For locally advanced disease (cT3 mrf+, cT4), the total dose should be ≥50.4 Gy 3
Important Clinical Considerations
Timing
- Surgery typically performed 6-8 weeks after completion of chemoradiotherapy 3
- Total neoadjuvant treatment duration (including chemotherapy and radiotherapy) should not exceed 6 months 1
Oxaliplatin Addition (Not Recommended)
Multiple randomized trials have shown that adding oxaliplatin to fluoropyrimidine-based chemoradiotherapy increases pathologic complete response rates but also significantly increases acute toxicity without clear long-term survival benefit 3, 7. Oxaliplatin is not routinely recommended as a radiosensitizer 7.
Common Pitfalls to Avoid
- Do not use bolus 5-FU as first-line: Continuous infusion or capecitabine are preferred due to better efficacy and toxicity profiles 6, 3, 7
- Monitor for dose-limiting toxicities: Diarrhea and stomatitis are the primary concerns, occurring in approximately 16% and 5% of patients respectively at standard doses 8
- Ensure adequate hydration and supportive care: Grade 3-4 gastrointestinal toxicity occurs in approximately 24.5% of patients 5
Special Populations
For elderly patients (≥80-85 years) or those with severe comorbidities who cannot tolerate chemoradiotherapy, short-course radiotherapy (25 Gy in 5 fractions) with delayed surgery may be considered instead 3.